Clinical trial
Safety of and Immune Response to a Human Parainfluenza Virus Vaccine…
NCT00308412 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00308412 |
|---|---|
| Title | Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants |
| Official title | Phase 1 Study to Determine the Safety, Infectivity, and Tolerability of Two Doses of Live Attenuated Recombinant Cold Passaged (cp) 45 Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3 102A, Delivered as Nose Drops to Infants 6 to 12 Months of Age, and to HPIV3 Seronegative Infants and… |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Johns Hopkins Bloomberg School of Public Health |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Paramyxoviridae Infections, Virus Diseases |
| Intervention type | Biological |
| Interventions | rHPIV3cp45, Placebo |
| Enrollment | 45 |
| Start date | Jun 1, 2006 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | Mar 29, 2006 |
| Last update posted | Jul 16, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: